- Previous Close
389.90 - Open
0.00 - Bid --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 417.70 - Volume
2,488 - Avg. Volume
27,838,270 - Market Cap (intraday)
35.354B - Beta (5Y Monthly) 0.23
- PE Ratio (TTM)
24.46 - EPS (TTM)
0.16 - Earnings Date Feb 27, 2025
- Forward Dividend & Yield 0.07 (1.69%)
- Ex-Dividend Date Apr 24, 2025
- 1y Target Est
405.24
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
www.haleon.com24,561
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: HLN.L
View MorePerformance Overview: HLN.L
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HLN.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HLN.L
View MoreValuation Measures
Market Cap
35.23B
Enterprise Value
43.13B
Trailing P/E
24.83
Forward P/E
20.53
PEG Ratio (5yr expected)
1.82
Price/Sales (ttm)
3.18
Price/Book (mrq)
2.18
Enterprise Value/Revenue
3.84
Enterprise Value/EBITDA
16.41
Financial Highlights
Profitability and Income Statement
Profit Margin
12.84%
Return on Assets (ttm)
4.55%
Return on Equity (ttm)
8.95%
Revenue (ttm)
11.23B
Net Income Avi to Common (ttm)
1.44B
Diluted EPS (ttm)
0.16
Balance Sheet and Cash Flow
Total Cash (mrq)
2.33B
Total Debt/Equity (mrq)
63.41%
Levered Free Cash Flow (ttm)
2.43B